Imagine a future where the global incident cases of liver cancer almost doubles, rising from 870 000 cases in 2022 to over ...

Researchers warn that the public, policy makers and even clinicians are not aware of the growing problem of liver cancer.

There's been plenty of buzz about this class of drug, following publication of a high-profile trial this year. How much do we ...

CagriSema vs placebo was associated with significant weight loss among adults with overweight or obesity with or without type 2 diabetes.

Researchers analyzed nearly 60,000 public Facebook posts to identify real-world adverse events linked to GLP-1 receptor ...